Sepsis is common among critically ill patients and is associated with significant mortality and morbidity (
1,
2). Despite advances in clinical care and outcomes, existing epidemiologic studies suggest that sepsis remains a major health problem worldwide (
3,
4). In 2017, more than 11 million sepsis-related deaths were reported, representing 19.7% of all global deaths (
5). Sepsis is treatable, and infection-prevention efforts can reduce sepsis incidence and improve outcomes (
6-
8). Recently, it has been found that vitamin D supplements can improve prognosis in patients with sepsis (
9,
10). Vitamin D plays an essential role in both the adaptive and innate immune systems for the ideal function of antimicrobial activity (
11-
13). Thus, it is a contributing factor to decreased sepsis incidence and severity (
13). However, patients with severe infections, such as those withsepsis, usually have a high rate of vitamin D insufficiency (
14-
16). Furthermore, several studies on patients with sepsis have shown strong associations between decreased vitamin D levels and adverse outcomes (i.e. increased length of stay, acute kidney injury, and mortality) (
17-
19). Although the role of vitamin D in sepsis has been previously suggested, the association of vitamin D with increased morbidity and mortality has not yet been established (
20-
22). In Iran, a high proportion of vitamin D deficiency was observed in the general population (
23). There is also an increasing number of patients with sepsis in healthcare settings (
24).